Total Cost of Ownership vs. Unit Price: Why Hospitals Evaluate Devices Differently Than You Think

Most device pitches lead with a price. Most hospital purchasing decisions are not made on one. The committee on the other side of the table is building a different number: what this device will cost the institution across a year of real use, net of whatever it changes about staffing, procedure time, consumables, downstream complications and the payment the hospital receives.

That number is total cost of ownership, and it is the reason a device that is twenty percent cheaper per unit routinely loses to one that is not.

What a value analysis committee is actually solving for

A hospital value analysis committee is a cross-functional group — clinical, supply chain, finance, sometimes infection prevention and biomedical engineering — with one job: decide whether adding this product improves care without worsening the institution's economics.

Three features of that job shape everything about how they read your pitch.

They are buying into a fixed payment. Inpatient care is largely paid at a bundled rate per admission and outpatient care through prospective payment groups. If your device adds cost inside a case whose payment does not change, the hospital absorbs the difference. If it removes cost or shortens stay, the hospital keeps the difference. That single fact explains most purchasing behaviour that vendors find irrational.

They are pricing switching, not just buying. Training hours, credentialing, new trays, storage, updated protocols, IT integration and the internal politics of changing a clinician's habitual choice are real costs, and they are front-loaded in year one.

And they are managing a portfolio. Standardising on fewer suppliers lowers administrative cost and improves contract terms. A marginally better product that fragments the catalogue often loses to a slightly worse one that consolidates it.

The components of total cost of ownership

When a committee models your device properly, the line items look roughly like this.

Acquisition cost — the unit price, less contracted discounts, times realistic annual volume rather than your forecast volume.

Consumables and disposables over the device's life. This is where capital equipment deals are won and lost: a favourable machine price attached to a proprietary consumable is a known pattern and experienced buyers model it immediately.

Service, maintenance, warranty and expected downtime. Downtime has a clinical cost as well as a financial one, and it is one of the few areas where references from peer institutions carry more weight than your data.

Training and workflow change — time, backfill, competency sign-off, and the productivity dip while a team learns.

Integration cost for anything that touches the record system, which for software is frequently larger than the licence itself.

Disposal, reprocessing and inventory carrying cost, including the space the product occupies and the expiry risk on stocked units.

Downstream clinical cost, positive or negative: complications, readmissions, revisions, avoided procedures, changed length of stay. This is the line where a well-evidenced device makes back a higher unit price, and the line where an unevidenced one has nothing to say.

Why cheaper devices lose

The most common failure is a pitch built entirely on the first line item. A twenty percent price advantage on a product that represents a small fraction of case cost is close to invisible in a total cost model, while a two-hour training burden across three hundred staff is not.

The second failure is claiming a saving the buyer does not receive. Societal savings, payer savings and savings that land in a different department's budget are all real, and none of them help the person deciding. If the benefit accrues to a budget the committee does not control, you need either a sponsor who does control it or a second argument that stands on its own.

The third is arriving without a model the committee can edit. Buyers trust numbers they can stress. A spreadsheet with visible assumptions, adjustable volumes and a clearly labelled source for every input survives scrutiny. A glossy one-pager with a single headline saving does not.

Building the case the committee will actually use

Start from their cost structure, not yours. Ask what the current pathway costs per case at this institution, and build the comparison in those units. Cost per case, cost per patient-year and cost per avoided event are all more persuasive than cost per unit.

Separate year one from steady state. Front-loaded switching costs are legitimate and buyers respect vendors who state them plainly, then show the crossover point.

Name the comparator honestly. Current practice at that hospital, not the older technology it replaced five years ago. A model benchmarked against a straw man is the fastest way to lose credibility with a committee that knows its own data.

Bring evidence that matches the claim. If you claim shorter length of stay, bring the study that measured length of stay. The HEOR evidence requirements by device category post covers what that means for software, implantables and diagnostics respectively, and the HEOR primer covers how to plan it early.

And bring a budget impact model, because that is the artifact the committee will circulate internally. Our market access guide sets out how it fits the wider access sequence.

What this means for pricing strategy

Total cost thinking changes how you price. It makes bundled pricing, risk-sharing and outcome-linked terms viable, because they move cost the buyer fears onto the party that believes the evidence. It also means a discount is often the weakest concession you can offer: paying for training, guaranteeing uptime or funding an integration usually buys more goodwill per dollar than a price cut, because it removes a line the committee is worried about rather than shaving one it has already accepted.

MedTech Compass scores markets on reimbursement environment and adoption readiness together, so you can see where hospital economics rather than regulatory timing is the binding constraint. If you want that applied to your product, book a walkthrough.

Hospitals are not being difficult when they ignore your unit price. They are doing the arithmetic their payment model forces on them. The vendors who win are the ones who do it first.

Sources

1. CMS — Acute Inpatient Prospective Payment System: https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps 2. CMS — Hospital Outpatient Prospective Payment System: https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient 3. AHRQ — Healthcare Cost and Utilization Project (HCUP): https://www.ahrq.gov/data/hcup/index.html 4. ECRI — independent evaluation of medical devices and health technology: https://www.ecri.org/ 5. ISPOR — Principles of Good Practice for Budget Impact Analysis II: https://www.ispor.org/heor-resources/good-practices/report/principles-of-good-practice-for-budget-impact-analysis-ii 6. NICE — Medical technologies evaluation programme: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-medical-technologies-evaluation-programme 7. Peterson Health Technology Institute — independent assessments of health technologies: https://phti.org/assessments/

This article is general information about hospital procurement and device economics, not legal, regulatory or financial advice.